He said that in the context of the data already having been released telling a compelling and consistent story of working well for all patients, including those who were on ERT and have since been withdrawn with no signs or plans of resuming. The drug works, there is no need to constantly provide incremental updates. 

 

How many BPs start doing CAR-Treg deals in the wake of AZ and Quell? Should SGMO bite early, or wait for the market there to go up a bit? They are best in class/first in class in CAR-Tregs after all.

 

Personally, don't care much either way, as the deal shows it's possible and they've guided to being open to taking on investment in this area. I wouldn't mind a couple more months to accumulate at these levels. 

 

It's pretty clear the death you keep referencing isn't actually ever going to happen.